{
  "description": null,
  "compose": {
    "include": [ {
      "valueSet": [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.226" ]
    }, {
      "valueSet": [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.188" ]
    }, {
      "valueSet": [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.189" ]
    }, {
      "valueSet": [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.181" ]
    }, {
      "valueSet": [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.178" ]
    }, {
      "valueSet": [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.179" ]
    }, {
      "valueSet": [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.184" ]
    }, {
      "valueSet": [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.187" ]
    } ]
  },
  "_filename": "del/ValueSet-2.16.840.1.113883.3.1444.5.231.json",
  "package_name": "us.nlm.vsac",
  "date": "2023-04-25T01:01:01-04:00",
  "meta": {
    "profile": [ "http://hl7.org/fhir/StructureDefinition/shareablevalueset", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm" ],
    "versionId": "7",
    "lastUpdated": "2023-04-25T01:01:01.000-04:00"
  },
  "publisher": "American Society of Clinical Oncology Steward",
  "jurisdiction": [ {
    "coding": [ {
      "code": "US",
      "system": "urn:iso:std:iso:3166"
    } ]
  } ],
  "purpose": "(Clinical Focus: The purpose of this value set is to represent concepts of medication Immune Checkpoint Inhibitor.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication immune checkpoint inhibitor: atezolizumab, LAG-3 inhibitor, avelumab, ipilimumab, durvalumab, nivolumab, pembrolizumab, cemiplimab; generic; prescribable; injectable.),(Exclusion Criteria: Excludes concepts that represent non-prescribable branded drugs, components or ingredients.)",
  "name": "ImmuneCheckpointInhibitor",
  "type": null,
  "experimental": null,
  "resourceType": "ValueSet",
  "expansion": {
    "total": 15,
    "contains": [ {
      "code": "1657005",
      "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
      "display": "40 ML ipilimumab 5 MG/ML Injection",
      "version": "11062023"
    }, {
      "code": "1657012",
      "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
      "display": "10 ML ipilimumab 5 MG/ML Injection",
      "version": "11062023"
    }, {
      "code": "1657190",
      "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
      "display": "4 ML nivolumab 10 MG/ML Injection",
      "version": "11062023"
    }, {
      "code": "1657195",
      "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
      "display": "10 ML nivolumab 10 MG/ML Injection",
      "version": "11062023"
    }, {
      "code": "1657746",
      "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
      "display": "pembrolizumab 50 MG Injection",
      "version": "11062023"
    }, {
      "code": "1657750",
      "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
      "display": "4 ML pembrolizumab 25 MG/ML Injection",
      "version": "11062023"
    }, {
      "code": "1792780",
      "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
      "display": "20 ML atezolizumab 60 MG/ML Injection",
      "version": "11062023"
    }, {
      "code": "1875542",
      "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
      "display": "10 ML avelumab 20 MG/ML Injection",
      "version": "11062023"
    }, {
      "code": "1919507",
      "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
      "display": "2.4 ML durvalumab 50 MG/ML Injection",
      "version": "11062023"
    }, {
      "code": "1919515",
      "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
      "display": "10 ML durvalumab 50 MG/ML Injection",
      "version": "11062023"
    }, {
      "code": "1991412",
      "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
      "display": "24 ML nivolumab 10 MG/ML Injection",
      "version": "11062023"
    }, {
      "code": "2058830",
      "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
      "display": "7 ML cemiplimab-rwlc 50 MG/ML Injection",
      "version": "11062023"
    }, {
      "code": "2119695",
      "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
      "display": "14 ML atezolizumab 60 MG/ML Injection",
      "version": "11062023"
    }, {
      "code": "2569080",
      "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
      "display": "12 ML nivolumab 10 MG/ML Injection",
      "version": "11062023"
    }, {
      "code": "2596778",
      "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
      "display": "20 ML nivolumab-rmbw 12 MG/ML / relatlimab-rmbw 4 MG/ML Injection",
      "version": "11062023"
    } ],
    "timestamp": "2023-11-26T19:56:37-05:00",
    "identifier": "urn:uuid:39e8ac7f-27e1-4ab4-8675-c43d3a9c5213"
  },
  "title": "Immune Checkpoint Inhibitor",
  "package_version": "0.18.0",
  "extension": [ {
    "url": "http://hl7.org/fhir/StructureDefinition/valueset-author",
    "valueString": "American Society of Clinical Oncology Author"
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
    "valueDate": "2023-04-25"
  }, {
    "url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
    "valueDate": "2023-04-25"
  } ],
  "status": "active",
  "id": "cd95e79f-79cc-4365-859b-288775de69bb",
  "kind": null,
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.231",
  "identifier": [ {
    "value": "urn:oid:2.16.840.1.113883.3.1444.5.231",
    "system": "urn:ietf:rfc:3986"
  } ],
  "version": "20230425"
}